|
||||||||||||||||
| HUM-MOLGEN -> Events -> Meetings and Conferences | ||||||||||||||||
| Strategies for High Throughput Screening | ||||||||||||||||
| August 23, 2002 | ||||||||||||||||
|
marcus evans, London, England 29-30 January 2003 marcus evans' International High Throughput Screening Conference will examine the key issues to reveal the commercial and scientific reality of HTS strategies for drug discovery. This event will involve original and in-depth firsthand experiences from leaders in the pharmaceutical market worldwide. The creation of quality data and data libraries, assay development, miniaturisation, automation and future implications of in silico technologies will be analysed in detail to ensure industry players discuss and learn how to boost profits and achieve ROI. |
||||||||||||||||
| Organized by: | marcus evans | |||||||||||||||
| Invited Speakers: | Richard Wildonger, Director, High Throughput Technologies, AstraZeneca R&D Boston. Frank Oehlenschlager, Head of Screening, Aventis France. Martin J. Valler, Group Leader HTS, Boehringer Ingelheim Pharma KG. Alan Wilson, Group Head Emerging Technologies & In Silico Development, Pharmacia Corporation. Will Kuijpers, Section Head, HTS & Technology, Lead Discovery Unit, NV Organon. Peter Simpson, Section Head, Automated Imaging, Merck Sharp & Dohme. Andrew Miranker, Professor, Department of Molecular BioChemistry & BioPhysics, Yale University. Jonathan Cooper, Professor of BioElectronics & BioEngineering, University of Glasgow. and etc... |
|||||||||||||||
| Deadline for Abstracts: | ||||||||||||||||
| Registration: | ||||||||||||||||
| E-mail: | olas@marcusevansuk.com | |||||||||||||||
| Posted by: | Ola Samuelsson | |||||||||||||||
| Host: | 194.74.216.2 | |||||||||||||||
|
||||||||||||||||
|
Generated by meetings and positions 5.0 by Kai Garlipp |
||||||||||||||||